|
|
Article: Dyax Announces Developments in Licensing and Funded Research Program.
- Article from:
- Business Wire
- Article date:
- August 26, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LFRP Collaborators Now Report One Approved Product, Fifteen Clinical-Stage Candidates and Dyax Reports Three New Technology License Agreements
CAMBRIDGE, Mass. -- Dyax Corp. (NASDAQ:DYAX) announced today successful advancement into Phase 1 clinical trials of two candidates identified using Dyax's proprietary phage display technology by licensees of the Company's Licensing and Funded Research Program (LFRP).
LFRP licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, recently announced it initiated clinical development for oncology candidate IMC-EB10, ImClone's anti-FLT3 antibody, for the treatment of acute myelogenous leukemia. ...